Oakview Dermatology LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,320	1
2024	Research	$29,727	2
2023	Research	$35,084	3
2022	Research	$13,230	6
2021	Research	$11,180	4
2020	Research	$19,780	4
2019	Research	$21,930	2

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $75,556 6 payments
AbbVie, Inc. $59,120 15 payments
Eli Lilly and Company $575 1 payment

Studies the money was for Research payments · program years 2019–2025

P10-023 $41,710 6 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihistamines $36,172 2 payments
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $28,064 2 payments
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Open-Label Extension Study Followed By Long-Term Open-Label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (Lou064) in Adult Chronic Spontaneous U $11,320 2 payments
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis (PS) $11,180 4 payments
Chronic Plaque Psoriasis (PS) Registry $6,230 5 payments
Psosa (Psoriasis Special Areas) - A US-Based Single-Arm Prospective Multicenter Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated With Ixekizumab $575 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.